Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Reports Highlight Urgency Of Rethinking Drug Investment And Procurement Reform

Medicines For Europe Has Called For Clearer Legal Guidance On Generic And Biosimilar Policies

Executive Summary

Medicines for Europe has responded to two recent publications from the European Commission, calling for policy reforms to support the role of generic and biosimilar medicines.

You may also be interested in...

Joined-Up Approach Must Underpin European Biosimilar Procurement

A more joined-up approach is needed on European procurement if the biosimilars market is to remain sustainable in the face of pricing and cost pressures, according to a discussion by industry stakeholders at Medicines for Europe’s 18th Biosimilar Medicines Conference.

New EU Rules Imminent On Joint Procurement Of Vaccines & Drugs In Health Crises

EU legislation just approved by legislators will require the European Commission to provide information on prices, manufacturers, delivery time frames and joint procurement processes for vaccines and medicines used in tackling future health crises such as pandemics.

Medicines For Europe Finds Inequitable Essential Medicines Access In CEE Countries

Countries across Central and Eastern Europe are failing to reap the full benefit of generic and biosimilar competition, according to a new report from Medicines for Europe.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts